Enterprise Angels

Mastaplex

Agri-Business

Transaction Size
NZD $1,000,000.00
Share Price
Minimum Investment
NZD $5,000.00
Issue Type
Agri-Business
Sector
Agri-Tech

The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.

If you are a wholesale investor under the definition of that term in clause 3 of Part 1 Schedule 1 of the Financial Markets Conduct Act 2013, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.

You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.

Background

The dairy industry faces a critical need for reliable mastitis diagnostics. Bovine mastitis costs the industry $35B annually and affects 100M cows globally, presenting a significant gap in the market. Mastaplex’s flagship product, Mastatest, is uniquely positioned to address this gap. It offers a cloud-based on-farm mastitis diagnostic system that enables real-time decision making, accurately identifying mastitis pathogens and their antibiotic sensitivities within 24 hours. This data seamlessly integrates into farm management systems, enhancing milk quality and promoting responsible antibiotic usage.

The team at Mastaplex is led by founder and CEO Olaf Bork, who brings experience from Bayer, one of the largest pharmaceutical and biotechnology companies. The board and advisors are equally experienced, with individuals like Ben Russell (ex CEO Argenta), Karl Gradon (CEO Miraka), and Matt Comer lending their expertise to the Company.

Since its 2018 launch, Mastatest has gained strong customer adoption. Customer satisfaction is high, with 96% recommending Mastatest. Two patents for the proprietary tech have been granted in key global dairy markets.

Capital Raise

  • Mastaplex are raising $200k-$1m to accelerate growth.
  • Funds will be used to scale operations and enhance product development.

If you’re interested in investing in Mastaplex, and would like more investor information, please register your interest below to receive:

  • Summary Pitch Deck
  • Information Memorandum
  • Term Sheet

Note: Minimum investment parcel is $5,000. You will be charged an admin fee upon investment, along with an exit fee on divestment. For more fee info please check here.

 

No items found.

Join our Business/Issuer newsletter

Our quarterly Issuer newsletter is for businesses and issuers, and contains platform updates and business insights.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Wholesale
Enterprise Angels

Mastaplex

Agri-Business

Register Interest

The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.

If you are a wholesale investor under the definition of that term in clause 3 of Part 1 Schedule 1 of the Financial Markets Conduct Act 2013, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.

You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.

Transaction Size
NZD $1,000,000.00
Share Price
Minimum Investment
NZD $5,000.00
Issue Type
Agri-Business
Sector
Agri-Tech

Background

The dairy industry faces a critical need for reliable mastitis diagnostics. Bovine mastitis costs the industry $35B annually and affects 100M cows globally, presenting a significant gap in the market. Mastaplex’s flagship product, Mastatest, is uniquely positioned to address this gap. It offers a cloud-based on-farm mastitis diagnostic system that enables real-time decision making, accurately identifying mastitis pathogens and their antibiotic sensitivities within 24 hours. This data seamlessly integrates into farm management systems, enhancing milk quality and promoting responsible antibiotic usage.

The team at Mastaplex is led by founder and CEO Olaf Bork, who brings experience from Bayer, one of the largest pharmaceutical and biotechnology companies. The board and advisors are equally experienced, with individuals like Ben Russell (ex CEO Argenta), Karl Gradon (CEO Miraka), and Matt Comer lending their expertise to the Company.

Since its 2018 launch, Mastatest has gained strong customer adoption. Customer satisfaction is high, with 96% recommending Mastatest. Two patents for the proprietary tech have been granted in key global dairy markets.

Capital Raise

  • Mastaplex are raising $200k-$1m to accelerate growth.
  • Funds will be used to scale operations and enhance product development.

If you’re interested in investing in Mastaplex, and would like more investor information, please register your interest below to receive:

  • Summary Pitch Deck
  • Information Memorandum
  • Term Sheet

Note: Minimum investment parcel is $5,000. You will be charged an admin fee upon investment, along with an exit fee on divestment. For more fee info please check here.

 

No items found.